Cargando…
Fully closed cell sorter for immune cell therapy manufacturing
By analyzing patients treated with adoptive immune cell therapies, various immune cell phenotypes have been found in the starting and infused materials as determinants of sustained remission. The isolation of these specific phenotypes for clinical use requires current Good Manufacturing Practice (cG...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457513/ https://www.ncbi.nlm.nih.gov/pubmed/37637381 http://dx.doi.org/10.1016/j.omtm.2023.07.012 |
_version_ | 1785096951932387328 |
---|---|
author | Matsumoto, Masahiro Tashiro, Shinji Ito, Tatsumi Takahashi, Kazuya Hashimoto, Gakuji Kajihara, Junji Miyahara, Yoshihiro Shiku, Hiroshi Katsumoto, Yoichi |
author_facet | Matsumoto, Masahiro Tashiro, Shinji Ito, Tatsumi Takahashi, Kazuya Hashimoto, Gakuji Kajihara, Junji Miyahara, Yoshihiro Shiku, Hiroshi Katsumoto, Yoichi |
author_sort | Matsumoto, Masahiro |
collection | PubMed |
description | By analyzing patients treated with adoptive immune cell therapies, various immune cell phenotypes have been found in the starting and infused materials as determinants of sustained remission. The isolation of these specific phenotypes for clinical use requires current Good Manufacturing Practice (cGMP)-compliant cell-sorting technologies with multiparameter selection capabilities. Here, we developed a cGMP-requirement-applicable fully closed cell sorter that has a suction mechanism and multiparameter detection using two laser optical settings. Negative pressure generated by a change in the chamber volume at a sorting point allows the isolation of cells of interest with high viability and purity. Our study demonstrated that this microfluidic sorter enables the isolation of cells of interest at an effective rate of 7,000 sorts per second on average. A purity of 85.5% and 77.1% effective yield with 93.7% viability was obtained when applying a target population of 35.9% in total (lymphocyte+CD8+) at 15,000 events per second (2 × 10(7) cells/mL). The sorted gene-modified T cells maintain largely unaltered proliferation, antigen recognition, cytokine release, and cytotoxicity functionalities. |
format | Online Article Text |
id | pubmed-10457513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-104575132023-08-27 Fully closed cell sorter for immune cell therapy manufacturing Matsumoto, Masahiro Tashiro, Shinji Ito, Tatsumi Takahashi, Kazuya Hashimoto, Gakuji Kajihara, Junji Miyahara, Yoshihiro Shiku, Hiroshi Katsumoto, Yoichi Mol Ther Methods Clin Dev Original Article By analyzing patients treated with adoptive immune cell therapies, various immune cell phenotypes have been found in the starting and infused materials as determinants of sustained remission. The isolation of these specific phenotypes for clinical use requires current Good Manufacturing Practice (cGMP)-compliant cell-sorting technologies with multiparameter selection capabilities. Here, we developed a cGMP-requirement-applicable fully closed cell sorter that has a suction mechanism and multiparameter detection using two laser optical settings. Negative pressure generated by a change in the chamber volume at a sorting point allows the isolation of cells of interest with high viability and purity. Our study demonstrated that this microfluidic sorter enables the isolation of cells of interest at an effective rate of 7,000 sorts per second on average. A purity of 85.5% and 77.1% effective yield with 93.7% viability was obtained when applying a target population of 35.9% in total (lymphocyte+CD8+) at 15,000 events per second (2 × 10(7) cells/mL). The sorted gene-modified T cells maintain largely unaltered proliferation, antigen recognition, cytokine release, and cytotoxicity functionalities. American Society of Gene & Cell Therapy 2023-08-02 /pmc/articles/PMC10457513/ /pubmed/37637381 http://dx.doi.org/10.1016/j.omtm.2023.07.012 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Matsumoto, Masahiro Tashiro, Shinji Ito, Tatsumi Takahashi, Kazuya Hashimoto, Gakuji Kajihara, Junji Miyahara, Yoshihiro Shiku, Hiroshi Katsumoto, Yoichi Fully closed cell sorter for immune cell therapy manufacturing |
title | Fully closed cell sorter for immune cell therapy manufacturing |
title_full | Fully closed cell sorter for immune cell therapy manufacturing |
title_fullStr | Fully closed cell sorter for immune cell therapy manufacturing |
title_full_unstemmed | Fully closed cell sorter for immune cell therapy manufacturing |
title_short | Fully closed cell sorter for immune cell therapy manufacturing |
title_sort | fully closed cell sorter for immune cell therapy manufacturing |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457513/ https://www.ncbi.nlm.nih.gov/pubmed/37637381 http://dx.doi.org/10.1016/j.omtm.2023.07.012 |
work_keys_str_mv | AT matsumotomasahiro fullyclosedcellsorterforimmunecelltherapymanufacturing AT tashiroshinji fullyclosedcellsorterforimmunecelltherapymanufacturing AT itotatsumi fullyclosedcellsorterforimmunecelltherapymanufacturing AT takahashikazuya fullyclosedcellsorterforimmunecelltherapymanufacturing AT hashimotogakuji fullyclosedcellsorterforimmunecelltherapymanufacturing AT kajiharajunji fullyclosedcellsorterforimmunecelltherapymanufacturing AT miyaharayoshihiro fullyclosedcellsorterforimmunecelltherapymanufacturing AT shikuhiroshi fullyclosedcellsorterforimmunecelltherapymanufacturing AT katsumotoyoichi fullyclosedcellsorterforimmunecelltherapymanufacturing |